bioAffinity Technologies, Inc.
BIAFbioAffinity Technologies is a biotechnology company focused on the development of noninvasive diagnostic laboratory tests and targeted cancer therapeutics.
Earnings
Q3 2026 report
November 6, 2026Next report
Date not yet announcedCompetitors
By market cap
Profile
bioAffinity Technologies is a biotechnology company focused on the development of noninvasive diagnostic laboratory tests and targeted cancer therapeutics. The company utilizes a proprietary platform combining flow cytometry with automated AI-driven analysis to detect early-stage lung cancer and other respiratory diseases. Its core value proposition lies in providing high-sensitivity, cost-effective diagnostic tools that reduce the need for invasive procedures and improve patient outcomes through early detection.
A developer of a first-of-its-kind balanced diagnostic test that combines flow cytometry and AI to achieve high sensitivity and specificity for early-stage lung cancer detection.
FAQ
- What is bioAffinity Technologies, Inc.'s market cap?
- bioAffinity Technologies, Inc. (BIAF) has a market capitalization of $1.4M and trades on NASDAQ.
- Who are bioAffinity Technologies, Inc.'s competitors?
- bioAffinity Technologies, Inc.'s key competitors include Biodesix, Veracyte, Guardant Health, and others. These companies compete in similar markets and product categories.
- Who does bioAffinity Technologies, Inc. partner with?
- bioAffinity Technologies, Inc.'s notable partners include Cardinal Health, ICU Medical, University of Texas at San Antonio, and others.
- What subsidiaries does bioAffinity Technologies, Inc. have?
- bioAffinity Technologies, Inc.'s subsidiaries include Precision Pathology Laboratory Services (PPLS), OncoSelect Therapeutics, LLC.
- Where is bioAffinity Technologies, Inc. headquartered?
- bioAffinity Technologies, Inc. is headquartered in United States of America and employs approximately 75 people. It has been publicly traded since 2022.